source
- Recon: FDA identifies four deaths in Newron schizophrenia drug trials; Dutch court blocks subcutaneous Keytruda in eight Europea...Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 13d ago↗ source
- Cerevance's solengepras cuts Parkinson off-time by 0.6 hours in Phase 3, advancing toward FDA reviewCerevance, a spinout from Takeda, reported that a high 150‑mg dose of its Parkinson's drug solengepras reduced daily "off time" by an average of 0.61 hours compared with placebo in the Phase 3 ARIS…